Table 2 Medication use during the observation perioda
Young group (16–64, n = 9122) | Elderly group (65–74, n = 7155) | Older elderly group (75–, n = 6419) | P-valueb | |
|---|---|---|---|---|
During exposure to bDMARDs/JAKIs with or without methotrexate, % | ||||
TNF inhibitors | 67.3 | 56.6 | 51.0 | < 0.001 |
Infliximab | 12.6 | 6.1 | 2.6 | < 0.001 |
Etanercept | 20.6 | 18.0 | 17.2 | 0.001 |
Adalimumab | 18.8 | 10.1 | 6.3 | < 0.001 |
Golimumab | 15.4 | 22.3 | 25.5 | < 0.001 |
Certolizumab pegol | 6.8 | 4.9 | 2.9 | < 0.001 |
Tocilizumab | 28.0 | 24.9 | 21.0 | < 0.001 |
Abatacept | 14.4 | 27.8 | 38.4 | < 0.001 |
JAKIs | 6.0 | 7.5 | 7.0 | 0.034 |
Tofacitinib | 3.7 | 4.6 | 4.4 | 0.143 |
Baricitinib | 2.3 | 3.1 | 2.9 | 0.140 |
Methotrexate or any immunosuppressive DMARD use | 71.6 | 67.4 | 54.7 | < 0.001 |
Methotrexate | 63.0 | 52.9 | 37.7 | < 0.001 |
Taclolimus | 14.4 | 18.5 | 19.3 | < 0.001 |
Mizoribine | 2.3 | 3.6 | 3.8 | < 0.001 |
Leflunomide | 1.4 | 1.6 | 1.0 | 0.157 |
Oral CS use, % | 52.4 | 57.4 | 66.2 | < 0.001 |
Maximum dose of oral CS c≥ 10 mg/day, % | 19.5 | 18.6 | 21.7 | 0.017 |
Mean dose of oral CS c≥ 10 mg/day, % | 8.8 | 7.7 | 10.3 | 0.001 |
Mean dose of oral CS c≥ 7.5 mg/day, % | 11.6 | 12.0 | 15.5 | < 0.001 |
During exposure to MTX without a bDMARDs and with or without other csDMARDs, % | ||||
Any immunosuppressive DMARD use | 12.7 | 10.9 | 10.2 | < 0.001 |
Taclolimus | 10.7 | 9.4 | 8.3 | < 0.001 |
Mizoribine | 1.8 | 1.6 | 2.0 | 0.354 |
Leflunomide | 0.7 | 0.3 | 0.3 | 0.001 |
Oral CS use, % | 51.8 | 55.4 | 63.2 | < 0.001 |
Maximum dose of oral CS c≥ 10 mg/day, % | 22.2 | 20.1 | 22.2 | 0.016 |
Mean dose of oral CS c≥ 10 mg/day, % | 12.5 | 9.9 | 12.0 | < 0.001 |
Mean dose of oral CS c≥ 7.5 mg/day, % | 16.0 | 13.4 | 16.7 | < 0.001 |